Toxic multinodular goiter other diagnostic studies

Jump to navigation Jump to search

Toxic multinodular goiter Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Toxic multinodular goiter from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Toxic multinodular goiter other diagnostic studies On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Toxic multinodular goiter other diagnostic studies

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Toxic multinodular goiter other diagnostic studies

CDC on Toxic multinodular goiter other diagnostic studies

Toxic multinodular goiter other diagnostic studies in the news

Blogs on Toxic multinodular goiter other diagnostic studies

Directions to Hospitals Treating Toxic multinodular goiter

Risk calculators and risk factors for Toxic multinodular goiter other diagnostic studies

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:

Overview

The most important diagnostic test to differentiate thyroid nodules from each other is fine needle aspiration (FNA).

Other Diagnostic Studies

Fine needle aspiration

  • The most important diagnostic test to differentiate thyroid nodules from each other is fine needle aspiration (FNA).
  • Autonomously functioning ( hot) thyroid nodule is usually not an indication for fine-needle aspiration biopsy.

As FNA is considered as an aggressive procedure, the American Thyroid Association developed the following criteria for FNA indication:

  • Nodules ≥ 1 cm with intermediate or high suspicion US pattern
  • Nodules ≥ 1.5 cm with low suspicion US pattern
  • Nodules ≥ 2 cm with very low suspicion US pattern (e.g., spongiform). Observation an alternate option
  • For nodules that do not meet the above criteria, FNA is not required, including nodules < 1 cm (with some exceptions) and purely cystic nodules.[1]
  • Criteria for US-guided FNA:
    • A higher likelihood of either a nondiagnostic cytology (>25–50% cystic component)
    • A higher likelihood of sampling error
      • Difficult to palpate nodules
      • Posteriorly located nodules
  • FNA biopsy has a mean sensitivity higher than 80% and mean specificity higher than 90%.
  • The accuracy of FNAB in diagnosing thyroid conditions is influenced by pathologist's experience and the technical skill of the physician performing the biopsy.
  • Thyroid FNAB diagnostic categories and the respective risk of malignancy associated include:
    • Benign - < 1%
    • Atypia of undetermined significance (AUS) - 5-10%
    • Follicular neoplasm - 20-30%
    • Suspicious for malignancy - 50-75%
    • Malignant - 100%

References

  1. Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, Pacini F, Randolph GW, Sawka AM, Schlumberger M, Schuff KG, Sherman SI, Sosa JA, Steward DL, Tuttle RM, Wartofsky L (2016). "2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer". Thyroid. 26 (1): 1–133. doi:10.1089/thy.2015.0020. PMC 4739132. PMID 26462967.

Template:WH Template:WS